Dive Brief:
- Stereotaxis said Wednesday that it has agreed to acquire surgical robotics company Robocath for up to $45 million.
- The deal includes $20 million upfront plus additional payments of up to $25 million tied to regulatory and commercial milestones. The milestones include Food and Drug Administration clearance of Robocath’s next-generation system.
- The deal combines complementary robotic technologies for use in endovascular procedures in electrophysiology, interventional cardiology and neurointerventions, Stereotaxis said.
Dive Insight:
Robocath’s current system, called R-One+, is the only robot commercially available in Europe for percutaneous coronary interventions, according to Stereotaxis. Robocath has installed 15 of the systems worldwide.
The company, based in Rouen, France, is also developing a next-generation robot that is designed to enable simultaneous manipulation of up to five interventional devices. The initial first-in-human procedures were recently completed in France.
Stereotaxis plans to accelerate the development of Robocath’s next-generation system and pursue regulatory submissions in the U.S. and Europe within the next two years.
Stereotaxis’s magnetic navigation technology is used in ablation procedures to treat cardiac arrhythmias such as atrial fibrillation. The company’s latest robot, GenesisX, received FDA clearance in November and was designed to address hospital infrastructure challenges that slowed adoption of earlier versions of the technology.
Stereotaxis’ robot uses computer-controlled magnetic fields to enable navigation of the distal tip of interventional devices, while Robocath’s mechanical robotic platform provides multi-device control at the bedside.
Stereotaxis CEO David Fischel said acquiring Robocath will significantly strengthen the company’s position as a leading platform for the full spectrum of endovascular procedures.
“This transaction accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies, opens new avenues for growth, and supports other strategic opportunities being pursued by Stereotaxis,” Fischel said in a statement.
Robocath is expected to contribute about $2 million in annual revenue during the first year post-acquisition, Stereotaxis said. The acquisition is expected to become break-even by the third year.
Stereotaxis said it will pay for the acquisition of Robocath in cash or Stereotaxis common stock. The deal is expected to close in mid-2026, after which Robocath will operate as a subsidiary of Stereotaxis.
